Alimera Sciences revealed that Alimera Sciences Europe, its Irish-based European business, is set to introduce Iluvien for noninfectious posterior uveitis in France through its distribution partner, Horus Pharma S.A.S.
Horus has received pricing and reimbursement approval from the Economics Committee for Health Products, CEPS, for Iluvien to prevent relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye.
“With France, we have now expanded the posterior uveitis indication to the largest western European countries as planned,” Rick Eiswirth, President and Chief Executive Officer of Alimera, said in a company news release.
“Horus Pharma has grown France into the second largest Iluvien market for DME, based on demand, so we are now excited to see them launch behind this new indication, bringing reduced recurrence of this disease to many French patients,” Mr. Eiswirth added.
Iluvien is a sustained release intravitreal implant indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIPU).